SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · $150M equity offering

Vir Biotechnology, Inc. · 8-K filed Nov 13, 2026 at 21:47 ET

At the news

BEARISHIMPACT 5/10

8-K filed Nov 13, 2026 at 21:47 ET

Vir Biotechnology priced an underwritten public offering of 15,000,000 shares of common stock at $10.00 per share, with gross proceeds of $150 million and expected net proceeds of approximately $140.4 million ($161.5 million if the underwriters' 30-day option for an additional 2,250,000 shares is fully exercised). The offering follows a recent activist stake reduction and a preliminary prospectus supplement filed one day earlier, and proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes. The 8.8% dilution (based on 171.3M shares outstanding) is a material negative event for existing shareholders.

  • 15,000,000 shares offered at $10.00 per share, gross proceeds $150 million
  • Underwriters have 30-day option for up to 2,250,000 additional shares
  • Expected net proceeds of approximately $140.4 million ($161.5 million if option fully exercised)
  • Underwriting discount of $0.60 per share; underwriters pay $9.40 per share

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access